Bio-Rad Laboratories, Inc., Followed By Perkinelmer, Inc. And Qiagen Are Dominating the Market for Global Biomarker Market in 2016

Global Biomarker Market is expected to reach USD 85,927.95 million by 2024 from USD 28,091.78 million in 2016, at a CAGR of 15.1%. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Access Full Report:- Biomarkers MarketThe global biomarker market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. The global biomarker market is dominated by Bio-Rad Laboratories, Inc., followed by PerkinElmer, Inc. and Qiagen. Other players in this market include Merck & Co., Inc., EKF Diagnostics, Enzo biochem, Inc., Meso Scale Diagnostics, LLC, Singulex, Inc., Signosis, Inc., and Cisbio Bioassays among others holds 32.0% of the global biomarker market in 2016.


Founded in 1952 and headquartered in California, U.S. Bio-Rad laboratories, Inc. develops and commercializes the wide range of products and systems in the healthcare, life science research, analytical chemistry and few other areas, which is used for the separation of composite chemical and biological ingredients and for the analysis and purification of their components. Bio-Rad operates its business in two industry segments named as life science and clinical diagnostics. Clinical Diagnostics segment manufactures, commercializes informatics systems, test systems, test kits and quality controls for the clinical laboratories.

Bio-rad has its presence across the globe in United States, Australia, Greece, Portugal, Austria, Hong Kong, Russia, Belgium, France, Hungary, South Africa, Singapore, Brazil, India, Canada, Israel, South Korea, China, Italy, Spain, Czech Republic, Japan, Sweden, Denmark, Netherlands, Mexico, Switzerland, Egypt, Taiwan, Finland, New Zealand, Thailand, Norway, United Kingdom, Germany, and Poland.


Incorporated in 1947 and headquartered in Massachusetts, U.S. PerkinElmer, Inc. is a supplier and manufacturer of products, services and solutions for the food, diagnostics, industrial, environmental, life sciences research and laboratory services markets. The company operates its business through two business segments which includes discovery & analytical solutions and diagnostics. The diagnostics segment provides products and wide range of reagents, instruments, assay platforms, and software for hospitals, medical labs, clinicians, and medical research professionals. The segment focusses on the areas such as reproductive health, developing market diagnostics, and applied genomics.

PerkinElmer develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceutical products which are marketed directly or indirectly in U.S. and across the globe. The company commercializes products and services in over 150 countries.


Founded in 1984 and headquartered at Hilden, Germany, Qiagen is engaged in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company operates through different business segments, namely Next-Gen Sequencing, Molecular Diagnostic, Life Sconce Research, Animal and Vet. Testing, Bioinformatics and others. The molecular diagnostic segment includes Oncology, Infectious Disease, Tuberculosis Management, Transplantation Testing and Women’s health. Next-Gen Sequencing covers GeneReader NGS System and QIAseq NGS Solutions.

Qiagen has its operations across the North America, Europe, Middle East and Africa, Asia-Pacific and rest of world. Some of its subsidiaries include Exiqon (Denmark), Cellestis (Australia), Tiangen Biotech Co. Ltd. (Beijing), Qiagen Ltd. (India), Ipsogen SA (France) and many more subsidiaries across the globe.